Germantown, Md. , and State College, Pa. , Jan. 25, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-of-its-kind collaboration with Penn State University in the United States. Create a shared research and training center for the development of microbiome sciences.
The partnership between university and industry will serve as a beacon in this area through research into study opportunities that address challenging situations and gaps in microbiome studies, resulting in studies on a network of microorganisms that can live in combination in any given environment, adding humans. . body.
In doing so, this new partnership will provide QIAGEN with a site for new product progression as a testing center. It is also designed to offer important studies and industrial education opportunities for the next generation of scientists. This includes a Penn State graduate internship program. It is helping them prepare for careers in the biotechnology industry.
“This new partnership with Penn State, one of the leading school research institutes in the field of microbiome studies, is based on a shared vision of an interconnectedness between human, animal and ecosystem health. It will shape studies, education, and outreach. “We are a young microbiome science box, and we look forward to boosting the careers of a new generation of scientists interested in this box,” said Nitin Sood, senior vice president and head of QIAGEN’s life sciences business line. “In addition, it will foster relationships with the microbiome research network and allow us to further expand new products for microbiome studies, based on direct feedback from visitors. “
Seth Bordenstein, director of the One Health Microbiome Center, professor of biology and entomology, and Huck Professor of Microbiome Sciences at Penn State, said, “The vision of ‘One Health’ shared through QIAGEN and Penn State University is critical to microbiome research. We are pleased to partner with the leading provider of microbiome answers to equip researchers with the equipment needed to explore how microorganisms circulate through humans, animals, plants, and the environment, impacting the fitness of all those ecosystems. ” With this multi-year marriage, we will bridge the gap between industry and academia and shape the long-term of microbiome research.
Among the various projects of this partnership, the team will participate in the global science education program “Discover the microbes inside!The Wolbachia Project”. This program allows middle and high school students, as well as high school students, to learn about arthropods (animals without backbones with an external chitin skeleton, segmented structure, and jointed legs, as well as insects, spiders, mites, and crustaceans) and to gather clinical knowledge about the bacterial endosymbiont (one organism that lives inside another to gain the advantages of both) Wolbachia pipientis.
It is estimated that this bacterium is found in approximately 50% of the world’s arthropods and has been shown, for example, to block the replication of potentially deadly RNA viruses, such as dengue virus, West Nile virus and Zika virus[1]. , is used to decrease the transmission of these and other viruses that are spread through the bite of inflamed arthropods (arboviruses) [2]. Because of those real-world impacts, Wolbachia is used as a style organism to examine the interactions between animals and microbes, genetics. , evolution, ecology and human health.
Microbiome studies aim to explore the relationships between microorganisms such as bacteria, fungi, and viruses, and their hosts. This may help to better understand the effect of the microbiome on health, disease, and ecological processes to expand new diagnostic responses. and healing strategies.
The primary task of the One Health Microbiome Center (OHMC) at Penn State’s Huck Institutes of Life Sciences will be for QIAGEN to provide tools and kits to prepare and process microbial samples.
Penn State is among the 30 most sensible public study colleges in the United States, with more than $1. 2 billion in annual spending on studies. With more than 500 members, plus 125 universities on Penn State campuses and more than 42 departments, OHMC is one of the largest organizations of its kind in microbiome studies.
QIAGEN’s comprehensive microbiome portfolio encompasses tools for every aspect of the scientific workflow, including reliable sample preparation kits optimized for investigating challenging samples from environmental and human microbiomes. To ensure reproducibility, QIAGEN offers sample preparation automation for standardization and reliability. The extensive range of microbiome solutions also includes downstream processing technologies such as NGS, digital PCR (dPCR), or quantitative PCR (qPCR), all complemented by robust bioinformatics tools for seamless digital analysis.
Learn more about QIAGEN’s solutions for microbiome research athttps://www.qiagen.com/us/applications/microbiome.
About QIAGEN
QIAGEN N. V. , a holding company founded in the Netherlands, is the world’s leading provider of Sample to Insight solutions that enable consumers to obtain valuable molecular data from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA, and proteins. of blood, tissue, and other materials. Testing technologies make those biomolecules visual and analytical. Bioinformatics software and knowledge bases interpret knowledge to generate applicable and actionable insights. Automation answers are coupled into seamless, cost-effective workflows. QIAGEN supplies answers to more than 500,000 international consumers in the fields of molecular diagnostics (human health) and life sciences (university, R
About Pennsylvania State University
Penn State is a multi-campus, land-grant public university that educates scholars from around the world and American communities through integrated systems of training, scholarship and services. Penn State is an R1 university, a classification awarded through the Carnegie Foundation for the Advancement of Higher Education to America’s top educational institutions, achieving a record $1. 239 billion in educational spending this fiscal year 2022. 2023. The University’s interdisciplinary, collaborative and discovery-oriented studies and scholarship promote human and economic development, global understanding and the advancement of professional practice through the expansion of wisdom and its programs in herbal and implemented sciences, social sciences and behavior, engineering and technology. , arts and humanities, and an infinite number of professions. The University’s school project includes undergraduate, graduate, professional, continuing and extension education, presented through residential instruction and distance learning. Penn State’s educational systems are enriched by the talent, wisdom, diversity, creativity, and educational acumen of its faculty, scholars, and staff. As the only land-grant university in Pennsylvania, Penn State offers unprecedented access to education and public facilities to citizens of the Commonwealth and beyond. The University engages in collaborative activities with partners in the personal sector, education and governments around the world to generate, integrate, apply and disseminate knowledge valuable to society. For more information, stop by www. studies. psu. edu.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N. V. Category: Corporate
[1] Flores, Heater, A. et O’Neill, Scott L. : “Control of vector-borne diseases through the release of modified mosquitoes” Nature Reviews Microbiology, 2018. https://doi. org/10. 1038/s41579-018-0025 – 0 [2] O’Neill, Scott L. et al. : “Large-scale deployment of Wolbachia in the network of dengue and other Aedes-borne arboviruses” Gates Open Research, 2018. https://doi. org/10. 12688/ puertasopenres. 12844. 1